- Home
- PFN vs PHAT Comparison
PFN vs PHAT Comparison
Compare PFN & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFN
- PHAT
- Stock Information
- Founded
- PFN 2004
- PHAT 2018
- Country
- PFN United States
- PHAT United States
- Employees
- PFN N/A
- PHAT N/A
- Industry
- PFN Finance/Investors Services
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- PFN Finance
- PHAT Health Care
- Exchange
- PFN Nasdaq
- PHAT Nasdaq
- Market Cap
- PFN 625.5M
- PHAT 1.2B
- IPO Year
- PFN N/A
- PHAT 2019
- Fundamental
- Price
- PFN $7.40
- PHAT $17.72
- Analyst Decision
- PFN
- PHAT Strong Buy
- Analyst Count
- PFN 0
- PHAT 4
- Target Price
- PFN N/A
- PHAT $22.50
- AVG Volume (30 Days)
- PFN 331.7K
- PHAT 908.5K
- Earning Date
- PFN 01-01-0001
- PHAT 08-08-2024
- Dividend Yield
- PFN 11.66%
- PHAT N/A
- EPS Growth
- PFN N/A
- PHAT N/A
- EPS
- PFN N/A
- PHAT N/A
- Revenue
- PFN N/A
- PHAT $9,918,000.00
- Revenue This Year
- PFN N/A
- PHAT $6,512.02
- Revenue Next Year
- PFN N/A
- PHAT $292.78
- P/E Ratio
- PFN N/A
- PHAT N/A
- Revenue Growth
- PFN N/A
- PHAT N/A
- 52 Week Low
- PFN $5.94
- PHAT $6.07
- 52 Week High
- PFN $7.58
- PHAT $18.58
- Technical
- Relative Strength Index (RSI)
- PFN 65.40
- PHAT 78.90
- Support Level
- PFN $7.30
- PHAT $15.73
- Resistance Level
- PFN $7.39
- PHAT $18.58
- Average True Range (ATR)
- PFN 0.05
- PHAT 1.08
- MACD
- PFN 0.01
- PHAT 0.37
- Stochastic Oscillator
- PFN 82.76
- PHAT 86.41
About PFN PIMCO Income Strategy Fund II
PIMCO Income Strategy Fund II is a closed-ended fixed income mutual fund. The company's primary investment objective is to seek high current income, consistent with the preservation of capital. The fund invests in a range of securities, such as corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, municipal bonds and notes, short-term instruments, sovereign Issues, preferred Securities and others.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.